Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeanie Johnson Simpson

Physician Assistant, Medical Shawnee, OK Physician Assistant

NPI 1225094626 CMS profile 10521346

2400 N Harrison St, Shawnee, OK 74804

Open in the dashboard

General payments

$5,592

439 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeanie Johnson Simpson of Shawnee, OK is reported in the CMS Open Payments database as having received $5,592 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,369 99
2024 General $1,124 75
2023 General $918 79
2022 General $1,199 95
2021 General $983 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeanie Johnson Simpson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jeanie Johnson Simpson were reported at $1,369. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jeanie Johnson Simpson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $983 $156 $41–$563 $132
2022 $1,199 $185 $55–$649 $149
2023 $918 $199 $58–$717 $160
2024 $1,124 $206 $62–$740 $164
2025 $1,369 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,516 183 payments
  2. Novo Nordisk Inc $1,374 87 payments
  3. Lilly USA, LLC $591 46 payments
  4. AstraZeneca Pharmaceuticals LP $573 27 payments
  5. Otsuka America Pharmaceutical, Inc. $366 25 payments
  6. ITI, Inc. $277 13 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $251 21 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $110 5 payments
  9. Antares Pharma, Inc. $87 6 payments
  10. Amgen Inc. $81 4 payments
  11. Other $366 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,592 439 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,252 78 payments
  2. RYBELSUS $1,230 76 payments
  3. QULIPTA $656 74 payments
  4. UBRELVY $470 56 payments
  5. VRAYLAR $437 53 payments
  6. FARXIGA $394 16 payments
  7. REXULTI $366 25 payments
  8. CAPLYTA $277 13 payments
  9. MOUNJARO $268 17 payments
  10. TRINTELLIX $251 21 payments
  11. Other $2,232 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,162

Median for Physician Assistant: 241

Drug cost

$811,756

Median for Physician Assistant: $4,110

Branded share of claims

21.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 191 $228,270
Jardiance Empagliflozin Brand 70 $86,002
Mounjaro Tirzepatide Brand 55 $67,713
Tresiba Flextouch U-200 Insulin Degludec Brand 45 $59,154
Eliquis Apixaban Brand 61 $55,527
Farxiga Dapagliflozin Propanediol Brand 52 $53,241
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $40,385
Trulicity Dulaglutide Brand 15 $28,122
Myrbetriq Mirabegron Brand 36 $24,125
Glyxambi Empagliflozin/Linagliptin Brand 14 $21,436

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$59,907

Of which drugs: $3,504

Medicare patients

190

Average age 73

Services billed

2,000

134 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 37%
Ischemic heart disease 33%
Atrial fibrillation 17%
Depression 17%
Chronic kidney disease 16%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 38 38 $3,109
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 34 143 $128
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 100 $68
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 80 $27
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 120 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $195
$195 — —
Ozempic
  • Novo Nordisk Inc $187
$187 191 —
UBRELVY
  • AbbVie, Inc. $116
$116 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $106
$106 — —
QULIPTA
  • AbbVie, Inc. $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record